Target intelligence / Profile preview

Synaptic vesicle protein 2 and Synaptotagmin (SV2/Syt)

Target
SV2/Syt
Molecular classification
Synaptic vesicle protein, Receptor, Membrane protein, Calcium sensor
01

Overview

Synaptic vesicle protein 2 (SV2) and Synaptotagmin (Syt) are integral membrane proteins located on the luminal surface of synaptic vesicles within presynaptic nerve terminals. They serve as the high-affinity protein receptors for Botulinum neurotoxins (BoNTs), which are potent inhibitors of neurotransmitter release (Dong et al., 2006). SV2 isoforms (A, B, and C) are the primary receptors for BoNT/A, BoNT/D, BoNT/E, and BoNT/F, while Synaptotagmin I and II serve as receptors for BoNT/B and BoNT/G (Dong et al., 2003). Upon binding to these receptors during the process of vesicle recycling, the toxins are internalized via endocytosis into cholinergic neurons. Once inside, the light chain of the toxin is translocated into the cytosol, where it cleaves specific SNARE proteins (such as SNAP-25 or VAMP), effectively blocking the release of acetylcholine at the neuromuscular junction (Pirazzini et al., 2017). This mechanism is exploited therapeutically to treat conditions characterized by muscle overactivity, such as dystonia and spasticity, as well as chronic migraine and hyperhidrosis (StatPearls, 2023).

Other names
SV2SynaptotagminBotulinum neurotoxin receptorsBoNT receptorsSV2ASV2BSV2CSyt ISyt IISynaptic vesicle protein 2ASynaptotagmin-1Synaptotagmin-2
02

Mechanism of action

Botulinum neurotoxins bind to the luminal domains of SV2 or Synaptotagmin during vesicle recycling, facilitating their internalization into the presynaptic terminal where they subsequently cleave SNARE proteins to inhibit acetylcholine release.

03

Biological functions

Neurotransmitter release regulationSynaptic vesicle exocytosisCalcium-dependent membrane fusionVesicle traffickingCalcium sensing
04

Disease associations

Cervical dystoniaBlepharospasmChronic migraineHyperhidrosisMuscle spasticityBotulismStrabismus
05

Safety considerations

Distant spread of toxin effect (iatrogenic botulism)Antibody formation (immunogenicity)DysphagiaRespiratory failureMuscle weakness
06

Interacting drugs

OnabotulinumtoxinA

6 more in the full profile.

07

Biomarkers

Cleaved SNAP-25 (for BoNT/A activity)Cleaved VAMP-1/2 (for BoNT/B activity)Compound muscle action potential (CMAP) reduction

Beyond the preview

Go deeper on Synaptic vesicle protein 2 and Synaptotagmin (SV2/Syt).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Synaptic vesicle protein 2 and Synaptotagmin (SV2/Syt).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call